[go: up one dir, main page]

CL2011002905A1 - Metodos para analizar la sensibilidad celular a farmacos que comprende obtener muestras de pacientes, combinar a lo menos 35 de las alicuotas con una composicion de farmaco y medir apoptosis o agotamiento celular en por lo menos una poblacion de celulas en cada una de las por lo menos 35 alicuotas; dispositivo para analizar dicha sensibilidad. - Google Patents

Metodos para analizar la sensibilidad celular a farmacos que comprende obtener muestras de pacientes, combinar a lo menos 35 de las alicuotas con una composicion de farmaco y medir apoptosis o agotamiento celular en por lo menos una poblacion de celulas en cada una de las por lo menos 35 alicuotas; dispositivo para analizar dicha sensibilidad.

Info

Publication number
CL2011002905A1
CL2011002905A1 CL2011002905A CL2011002905A CL2011002905A1 CL 2011002905 A1 CL2011002905 A1 CL 2011002905A1 CL 2011002905 A CL2011002905 A CL 2011002905A CL 2011002905 A CL2011002905 A CL 2011002905A CL 2011002905 A1 CL2011002905 A1 CL 2011002905A1
Authority
CL
Chile
Prior art keywords
aliquots
sensitivity
analyze
combining
methods
Prior art date
Application number
CL2011002905A
Other languages
English (en)
Inventor
Juan Ballesteros
Sandra Sapia
Andrew Bosanquet
Julian Gorrochategui
Consuelo Tudela
Luis Ignacio Caveda
Pilar Hernandez
Teresa Bennett
Daniel Primo
Alberto Orfao
Coyt Jackson
Santiago Lago
Maria Matoses
Lilia Suarez
Original Assignee
Vivia Biotech Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42342776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002905(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vivia Biotech Sl filed Critical Vivia Biotech Sl
Publication of CL2011002905A1 publication Critical patent/CL2011002905A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Métodos para analizar la sensibilidad celular a fármacos que comprende obtener muestras de pacientes, combinar a lo menos 35 de las alicuotas con una composición de fármaco y medir apoptosis o agotamiento celular en por lo menos una población de células en cada una de las por lo menos 35 alicuotas; dispositivo para analizar dicha sensibilidad.
CL2011002905A 2009-05-19 2011-11-18 Metodos para analizar la sensibilidad celular a farmacos que comprende obtener muestras de pacientes, combinar a lo menos 35 de las alicuotas con una composicion de farmaco y medir apoptosis o agotamiento celular en por lo menos una poblacion de celulas en cada una de las por lo menos 35 alicuotas; dispositivo para analizar dicha sensibilidad. CL2011002905A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17968509P 2009-05-19 2009-05-19

Publications (1)

Publication Number Publication Date
CL2011002905A1 true CL2011002905A1 (es) 2012-07-13

Family

ID=42342776

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002905A CL2011002905A1 (es) 2009-05-19 2011-11-18 Metodos para analizar la sensibilidad celular a farmacos que comprende obtener muestras de pacientes, combinar a lo menos 35 de las alicuotas con una composicion de farmaco y medir apoptosis o agotamiento celular en por lo menos una poblacion de celulas en cada una de las por lo menos 35 alicuotas; dispositivo para analizar dicha sensibilidad.

Country Status (17)

Country Link
US (2) US20100298255A1 (es)
EP (1) EP2433124B1 (es)
JP (1) JP5851984B2 (es)
CN (1) CN102460165B (es)
AR (1) AR076590A1 (es)
AU (1) AU2010249593B2 (es)
BR (1) BRPI1012980A2 (es)
CA (1) CA2762783C (es)
CL (1) CL2011002905A1 (es)
DK (1) DK2433124T3 (es)
ES (1) ES2628219T3 (es)
IL (1) IL216419A (es)
MX (1) MX2011012267A (es)
RU (1) RU2636614C2 (es)
SG (2) SG10201402346UA (es)
TW (1) TWI546537B (es)
WO (1) WO2010135468A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130226469A1 (en) * 2008-04-01 2013-08-29 Purdue Research Foundation Gate-free flow cytometry data analysis
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
WO2012072823A1 (en) 2010-12-03 2012-06-07 Mindseeds Laboratories Srl Rapid screening of monoclonal antibodies
TWI503545B (zh) * 2010-12-24 2015-10-11 Methods of Screening Probiotics for Individual Differences
ES2567276T3 (es) * 2011-05-12 2016-04-21 Genentech, Inc. Método de LC-MS/MS de monitoreo de múltiples reacciones para detectar anticuerpos terapéuticos en muestras de animales usando péptidos de cambio de marco
EP2776032B1 (en) * 2011-11-09 2018-10-17 Bristol-Myers Squibb Company Treatment of hematologic malignancies with an anti-cxcr4 antibody
KR101327533B1 (ko) 2012-12-11 2013-11-08 사회복지법인 삼성생명공익재단 환자 맞춤형 항암제 선별용 시스템
CN105555961B (zh) * 2013-07-29 2021-04-27 加利福尼亚大学董事会 具有动态变化刺激的实时反馈系统控制技术平台
EP2959904A1 (en) 2014-06-27 2015-12-30 Institut De Recerca Contra La Leucemia Josep Carreras Methods for treating, diagnosing and prognosing a haematological malignancy
CN104606207A (zh) * 2015-02-09 2015-05-13 南京格耀生物科技有限公司 磺胺甲恶唑在制备抑制肿瘤细胞转移和扩散的药物中的应用
CN104958312A (zh) * 2015-05-14 2015-10-07 四川大学华西医院 一种治疗急性淋巴细胞白血病的联合用药物
WO2017077046A1 (en) * 2015-11-04 2017-05-11 Vivia Biotech, S.L An ex vivo method for testing cellular responsiveness of primary cell populations to a drug or combination of drugs
WO2017083592A1 (en) * 2015-11-11 2017-05-18 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
MX392707B (es) 2016-04-13 2025-03-24 Vivia Biotech Sl LINFOCITOS T ACTIVADOS POR BiTE EX VIVO.
CN106093394B (zh) * 2016-06-07 2017-12-26 中国人民解放军第二军医大学 Flt3蛋白在制备肝癌对索拉菲尼疗效评估试剂盒中的应用
US12138625B2 (en) 2016-06-14 2024-11-12 Cellply S.R.L Screening kit and method
US20210189336A1 (en) 2017-10-18 2021-06-24 Vivia Biotech, S.L. Bite-activated car-t cells
IL315839A (en) 2017-10-31 2024-11-01 Exscientia Gmbh Methods for determining selectivity of test compounds
US11116692B2 (en) 2018-06-07 2021-09-14 Gecko Alliance Group Inc. Method, system, computer program product and device for facilitating centralized control and monitoring over a network of a set of remote bathing unit systems
WO2020043716A1 (en) * 2018-08-27 2020-03-05 Katholieke Universiteit Leuven Pharmacological targeting of de novo serine/glycine synthesis
US20210358575A1 (en) * 2018-10-11 2021-11-18 Vivia Biotech Sl A method for determining the efficacy of treatment with a combination of drugs in a subject diagnosed with a disease and a method for classifying the utility of drug combinations in treatment of said subject
US20220011296A1 (en) * 2018-11-14 2022-01-13 Dana-Farber Cancer Institute, Inc. Determining treatment response in single cells
CN113748126A (zh) * 2018-11-30 2021-12-03 因提玛生物科学公司 鉴定免疫调节基因的方法
US12145000B2 (en) 2020-07-27 2024-11-19 Canon Medical Systems Corporation Radiotherapy support system and method
CN112569342A (zh) * 2020-12-21 2021-03-30 中南大学 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物
CN115531391B (zh) * 2022-11-03 2023-07-18 浙江大学 一种治疗白血病的药物及应用

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2947289A (en) * 1988-01-04 1989-08-01 Oncotech Incorporated Methods and apparatus assessing tumor resistance
US5366885A (en) * 1992-06-09 1994-11-22 Barranco Iii Sam C Method and kit for testing tumors for drug sensitivity
US5474909A (en) * 1992-08-07 1995-12-12 Anticancer, Inc. Noncolorimetric histoculture method for predicting drug response of tumors
AU2265695A (en) * 1995-01-17 1996-08-07 Pfizer Inc. The use of sertraline to treat cancer patients
US6825174B2 (en) * 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US5736129A (en) * 1995-11-17 1998-04-07 Medenica; Rajko D. Flow cytometric pharmacosensitivity assay and method of cancer treatment
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
DK0914102T3 (da) * 1996-05-24 2006-01-09 Angiotech Pharm Inc Præparater og fremgangsmåder til behandling eller forebyggelse af syddomme i legemskanaler
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US7026447B2 (en) * 1997-10-09 2006-04-11 Human Genome Sciences, Inc. 53 human secreted proteins
US20030049618A1 (en) * 1997-03-07 2003-03-13 Ruben Steven M. 186 human secreted proteins
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6207717B1 (en) * 1999-01-12 2001-03-27 Dow Corning Corporation Entrapment of vitamins with an elastomeric silicone polyether
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6911306B1 (en) * 1999-10-18 2005-06-28 Emory University TMS1 compositions and methods of use
WO2001032677A1 (en) * 1999-11-04 2001-05-10 Human Genome Sciences, Inc. Uteroglobin-like polynucleotides, polypeptides, and antibodies
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
CA2427858A1 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
WO2002046750A2 (en) * 2000-11-13 2002-06-13 Vanderbilt University Methods of predicting chemotherapy response
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
DE10064997A1 (de) * 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
DE60113731T2 (de) * 2001-01-31 2006-06-29 Pfizer Products Inc., Groton Als inhibitoren von pde4-isozymen geeignete etherderivate
US7199124B2 (en) * 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
DE50212958D1 (de) * 2001-02-14 2008-12-11 Evotec Ag Dispensionsvorrichtung
JP4634694B2 (ja) * 2001-03-23 2011-02-16 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪アルコール薬物複合体
AU2002256359A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US20030147887A1 (en) * 2001-11-02 2003-08-07 Shen-Wu Wang B-cell lymphoma specific antigen for use in diagnosis and treatment of B-cell malignancies
WO2003062792A2 (en) * 2002-01-22 2003-07-31 Trustees Of The University Of Pennsylvania Methods for determining drug responsiveness
GB0202337D0 (en) * 2002-02-01 2002-03-20 Univ Birmingham Cancer treatment
GB0203276D0 (en) * 2002-02-12 2002-03-27 Novartis Ag Organic compounds
DE10214388A1 (de) * 2002-03-30 2003-10-16 Cognis Deutschland Gmbh Verfahren zur Herstellung fester Mittel
US7326733B2 (en) * 2002-05-31 2008-02-05 The Forsyth Institute Methods for increasing bone density
US20040077601A1 (en) * 2002-07-09 2004-04-22 Point Therapeutics, Inc. Methods and compositions relating to isoleucine boroproline compounds
CN1389462A (zh) * 2002-07-12 2003-01-08 复旦大学 大叶蒟素及其同系物，和在制备药物组合物中的应用
US20060009378A1 (en) * 2002-11-14 2006-01-12 Itshak Golan Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
US20040101477A1 (en) * 2002-11-27 2004-05-27 Xanthus Life Sciences, Inc. Individualization of therapy with anesthetics
WO2004091572A2 (en) * 2003-04-09 2004-10-28 Biodelivery Sciences International, Inc. Cochleate compositions directed against expression of proteins
WO2004091578A2 (en) * 2003-04-09 2004-10-28 Biodelivery Sciences International, Inc. Novel encochleation methods, cochleates and methods of use
US7329638B2 (en) * 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
US20050136043A1 (en) * 2003-08-07 2005-06-23 Ludwig Institute For Cancer Research TGFbeta signaling inhibitors
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
US9149440B2 (en) * 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
US20060127404A1 (en) * 2003-09-30 2006-06-15 Chichi Huang Hinge core mimetibodies, compositions, methods and uses
US20050143378A1 (en) * 2003-12-29 2005-06-30 Yun Anthony J. Treatment of conditions through pharmacological modulation of the autonomic nervous system
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
AU2004291102A1 (en) * 2003-11-13 2005-06-02 Board Of Regents, The University Of Texas System Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure
US7211275B2 (en) * 2004-01-16 2007-05-01 Massachusetts Institute Of Technology Composite materials for controlled release of water soluble products
BRPI0507859A (pt) * 2004-02-19 2007-07-17 Novartis Ag uso dos inibidores da colinesterase
RU2574926C9 (ru) * 2004-05-03 2020-06-16 Ипсен Биофарм Лтд. Липосомные композиции, используемые для доставки лекарственных средств
WO2006088491A2 (en) * 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US20060009506A1 (en) * 2004-07-09 2006-01-12 Odyssey Thera, Inc. Drugs for the treatment of neoplastic disorders
ES2341559T3 (es) * 2004-07-23 2010-06-22 The Medicines Company (Leipzig) Gmbh Pirido(3',2':4,5)tieno(3,2-d)pirimidinas y pirido(3',2':4,5)furo(3,2-d)pirimidinas sustituidas para su utilizacion como inhibidores de la liberacion de pda-4 y/o tnf-alfa.
US7566548B2 (en) * 2004-08-13 2009-07-28 University Of Massachusetts Methods for identifying therapeutic agents and for treating disease
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
EP1627610A1 (en) * 2004-08-21 2006-02-22 TLT Medical Ltd Drug delivery throug application in nails
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
WO2006031767A2 (en) * 2004-09-10 2006-03-23 Otologics, Llc Adjustable bone bracket
US20060058966A1 (en) * 2004-09-15 2006-03-16 Bruckner Howard W Methods and systems for guiding selection of chemotherapeutic agents
US20060062734A1 (en) * 2004-09-20 2006-03-23 Melker Richard J Methods and systems for preventing diversion of prescription drugs
EP1809104A4 (en) * 2004-09-23 2009-04-29 Alexander Michalow METHODS FOR REGULATING NEUROTRANSMITTER SYSTEMS BY INDUCING COUNTER-ADAPTATIONS
US20070292523A1 (en) * 2004-09-27 2007-12-20 Joey Moodley Dihydropyrimidine Formulations
JP4772055B2 (ja) * 2004-10-20 2011-09-14 日立化成工業株式会社 ｍＲＮＡの定量により薬剤の投与を選定する方法
BRPI0517925A (pt) * 2004-11-02 2008-10-21 Pfizer derivados de sulfonil benzimidazol
EP1814390A4 (en) * 2004-11-12 2009-07-01 Univ Northwestern METHOD FOR THE TREATMENT OF MOLECULAR BLOOD DISEASES WITH NUCLEOSIDE ANALOGUE
US20080096872A1 (en) * 2004-12-22 2008-04-24 Friedman Robert S Composition for Treatment of Pain Specification
EP1861356A1 (en) * 2005-02-01 2007-12-05 Icagen, Inc. Imines as ion channel modulators
CN1834659A (zh) * 2005-03-17 2006-09-20 希森美康株式会社 试料分析装置和试料分析方法以及血液分析装置
WO2007053189A2 (en) * 2005-06-01 2007-05-10 Northwestern University Compositions and methods for altering immune function
US7655421B2 (en) * 2005-06-17 2010-02-02 Ciencia, Inc. Cytometer on a chip
PL1896073T3 (pl) * 2005-06-30 2013-08-30 Janssen Biotech Inc Przeciwciała anty-IL-23, kompozycje, sposoby i zastosowania
WO2007011292A1 (en) * 2005-07-21 2007-01-25 Astrazeneca Ab N-benzyl-morpholine derivatives as modulators of the chemokine receptor
WO2007015926A2 (en) * 2005-07-25 2007-02-08 Oregon Health And Science University Multiparameter flow cytometric cytometric cytotoxicity systems, methods, compositions and kits for evaluating the susceptibility of cancer
TW200745106A (en) * 2005-10-03 2007-12-16 Astrazeneca Ab Chemical compounds
KR20080028857A (ko) * 2005-10-05 2008-04-01 아스트라제네카 유케이 리미티드 ＥｒｂＢ 수용체 약물에 대한 환자반응을 예측 및 모니터링하는 방법
US20080318252A1 (en) * 2007-04-23 2008-12-25 Scott Kachlany Rapid assay to test anti-cancer drugs under physiological conditions
BRPI0619126A2 (pt) * 2005-12-02 2011-09-13 Pfizer Ltd derivados espirocìclicos, composição farmacêutica e usos dos mesmos
EP1973527B1 (en) * 2005-12-15 2009-10-07 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for parenteral administration
CN101460060A (zh) * 2006-03-01 2009-06-17 特莱斯特拉塔公司 局部治疗焦油响应性皮肤病用的组合物和方法
ATE484497T1 (de) * 2006-03-06 2010-10-15 Raqualia Pharma Inc Sulfonylbenzimidazolderivate
EP1996551A2 (en) * 2006-03-07 2008-12-03 AstraZeneca AB Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them.
US20090029958A1 (en) * 2006-03-08 2009-01-29 Lilian Alcaraz Phenethanolamine derivatives as beta2 adrenoreceptor agonists
TW200808763A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
US20100009352A1 (en) * 2006-05-24 2010-01-14 Gough Albert H Method for Modeling a Disease
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
CN101511775A (zh) * 2006-06-29 2009-08-19 詹森药业有限公司 丁基和丁炔基苄基胺化合物
WO2008021088A2 (en) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
US20080066739A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
JP5388854B2 (ja) * 2006-09-26 2014-01-15 セルジーン コーポレイション ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法
US8841300B2 (en) * 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
MX337906B (es) * 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
US7661326B2 (en) * 2006-10-26 2010-02-16 Beckman Coulter, Inc. Apparatus for aspirating and dispensing liquids in an automated analyzer
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
GB0625322D0 (en) * 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
CA2677498C (en) * 2007-02-05 2016-05-17 Carbylan Biosurgery, Inc. Polymer formulations for delivery of bioactive agents
GB0704000D0 (en) * 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
BRPI0808445A2 (pt) * 2007-03-07 2014-08-05 Janssen Pharmaceutica Nv TIAZOLIDINADIONAS COMO MODULADORES DE RECEPTOR-a RELACIONADOS COM ESTROGÊNIO
GB0707127D0 (en) * 2007-04-13 2007-05-23 Zysis Ltd Pharmaceutical compositions
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
US7943658B2 (en) * 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
PL2200588T3 (pl) * 2007-09-25 2019-09-30 Solubest Ltd. Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania
US8354417B2 (en) * 2007-09-26 2013-01-15 Celgene Corporation Solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same
US9125384B2 (en) * 2007-10-18 2015-09-08 Riken Mouse having human leukemic stem cell and leukemic non-stem cell amplified therein, and method for production thereof
US9115061B2 (en) * 2007-10-19 2015-08-25 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
CN101896184A (zh) * 2007-10-19 2010-11-24 伯恩哈姆医学研究协会 抗凋亡蛋白抑制剂
WO2009089011A2 (en) * 2008-01-08 2009-07-16 Sirtris Pharmaceuticals, Inc. Resveratrol formulations
CA2721065C (en) * 2008-05-27 2016-09-27 Astrazeneca Ab Phenoxypyridinylamide derivatives and their use as pde4 inhibitors
US8227202B2 (en) * 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
US20100099109A1 (en) * 2008-10-17 2010-04-22 Nodality, Inc., A Delaware Corporation Methods for Analyzing Drug Response
KR101046883B1 (ko) * 2008-11-19 2011-07-06 재단법인 아산사회복지재단 항암제 치료약제에 대한 감수성을 일괄적으로 결정하는 방법

Also Published As

Publication number Publication date
RU2011148289A (ru) 2013-06-27
IL216419A (en) 2016-05-31
CA2762783A1 (en) 2010-11-25
DK2433124T3 (en) 2017-06-19
US20100298255A1 (en) 2010-11-25
CN102460165A (zh) 2012-05-16
SG10201402346UA (en) 2014-10-30
TW201043955A (en) 2010-12-16
JP5851984B2 (ja) 2016-02-03
AU2010249593B2 (en) 2016-03-17
EP2433124B1 (en) 2017-03-01
MX2011012267A (es) 2012-04-11
TWI546537B (zh) 2016-08-21
IL216419A0 (en) 2012-02-29
EP2433124A1 (en) 2012-03-28
AU2010249593A1 (en) 2012-01-12
JP2012527627A (ja) 2012-11-08
US20170205395A1 (en) 2017-07-20
ES2628219T3 (es) 2017-08-02
CA2762783C (en) 2018-06-26
RU2636614C2 (ru) 2017-11-24
AR076590A1 (es) 2011-06-22
BRPI1012980A2 (pt) 2016-03-29
SG176571A1 (en) 2012-01-30
CN102460165B (zh) 2016-08-17
WO2010135468A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
CL2011002905A1 (es) Metodos para analizar la sensibilidad celular a farmacos que comprende obtener muestras de pacientes, combinar a lo menos 35 de las alicuotas con una composicion de farmaco y medir apoptosis o agotamiento celular en por lo menos una poblacion de celulas en cada una de las por lo menos 35 alicuotas; dispositivo para analizar dicha sensibilidad.
MX2019009612A (es) Metodos de elaboracion de perfiles especificos al tipo celular para identificar objetivos de farmacos.
BR112012031071A2 (pt) 8-proteínas de ligação à il-1
BR112015026222A2 (pt) dispositivo de coleta de amostra de fluido biológico
CL2010001023A1 (es) Metodo para tomar muestras de semillas que consisten en separar una muestra proveniente del resto de una semilla y trasladar la muestra a una ubicacion predeterminada para un uso posterior.
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
DOP2006000182A (es) Medidor con alarma de tiempo postprandial para efectuar determinaciones
SV2011003888A (es) Compuestos que expanden las celulas madre hematopoieticas
BR112015026248A2 (pt) dispositivo de coleta de fluido biológico e sistema de separação e teste de fluido biológico
MX366369B (es) Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo.
GB2474146A (en) Methods of determining the health status of an individual
MX2015014484A (es) Dispositivo de recogida de fluidos biologicos y sistema de separacion y analisis de fluidos biologicos.
GT201400099A (es) Proteínas que pueden unirse a la il-1
BRPI1014652A2 (pt) sensor eletroquímico amperométrico, método para fabricar o mesmo, sonda amperométrica de medição do teor de uma substância de oxirredução dissolvida em um líquido e uso de um sensor.
EP4273551A3 (en) Multiplexed total antibody and antibody-conjugated drug quantification assay
MX376300B (es) Detección de factores de virulencia microbiana bucal.
MX2016010432A (es) Tratamiento de muestras de sangre usando espuma de celdas abiertas.
DE602005015559D1 (de) Pharmakodynamische tests mit durchflusszytometrie
EP2147290A4 (en) METHOD FOR PREPARING A CELL SAMPLE AND APPARATUS THEREOF
GB201113814D0 (en) Materials and methods for determining sensitivity potential of compounds
CY1121482T1 (el) Ευαισθητη πολυπλεκτικη ανοσοδοκιμασια για τους διαλυτους υποδοχεις των αυξητικων παραγοντων των ινοβλαστων
AR085164A1 (es) Metodos para el analisis de la placa
MX2021015057A (es) Anticuerpos anti-talen y usos de los mismos.
Dominguez Lara Psychometric Properties of a Quality of Life Scale for Adults with Intellectual Disabilities
GB0225885D0 (en) Quantifying exposure to stress